Cargando…

Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia

BACKGROUND: Flomoxef is potentially effective against β-lactamase-producing Enterobacteriaceae because limited clinical data demonstrate its effectiveness against Enterobacteriaceae bloodstream infections (BSIs) based on its minimum inhibitory concentrations (MICs). This study was conducted to deter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chen-Hsiang, Chen, I-Ling, Li, Chia-Chin, Chien, Chun-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267728/ https://www.ncbi.nlm.nih.gov/pubmed/30568470 http://dx.doi.org/10.2147/IDR.S185670

Ejemplares similares

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniae in patients on maintenance hemodialysis
por: Yang, Chih-Chao, et al.
Publicado: (2012)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021)

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
por: Darlow, Christopher A., et al.
Publicado: (2022)

Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022)

Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)

2778. Retrospective evaluation of effectiveness of Flomoxef for infections due to extended-spectrum β-lactamase-producing Enterobacterales
por: Koizumi, Ryuji, et al.
Publicado: (2023)

In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
por: Yamashiro, Hidenori, et al.
Publicado: (2023)

A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia
por: Yap, Polly Soo Xi, et al.
Publicado: (2023)

In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Associated with Urinary Tract Infections in Malaysia
por: Ngoi, Soo Tein, et al.
Publicado: (2021)

Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
por: Darlow, Christopher A, et al.
Publicado: (2022)

The Genotypic and Phenotypic Characteristics Contributing to Flomoxef Sensitivity in Clinical Isolates of ESBL-Producing E. coli Strains from Urinary Tract Infections
por: Sakaeda, Kazuma, et al.
Publicado: (2023)

Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
por: Horie, Akiyoshi, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function
por: Hamada, Yukihiro, et al.
Publicado: (2022)

The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia
por: Fu, Chien-Fang, et al.
Publicado: (2018)

Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations
por: Mills, Alexandra G., et al.
Publicado: (2023)

Impact of teicoplanin maintenance dose and MIC values on the clinical outcomes of patients treated for methicillin-resistant Staphylococcus aureus bacteremia
por: Tsai, Ching-Yen, et al.
Publicado: (2018)

Antibiotic Susceptibility and Minimum Inhibitory Concentration for Stenotrophomonas maltophilia Ocular Infections
por: Ho, Margaret Ming-Chih, et al.
Publicado: (2022)

Using random forest to predict antimicrobial minimum inhibitory concentrations of nontyphoidal Salmonella in Taiwan
por: Wang, Chia-Chi, et al.
Publicado: (2023)

Antimicrobial Susceptibility, Minimum Inhibitory Concentrations, and Clinical Profiles of Stenotrophomonas maltophilia Endophthalmitis
por: Ho, Ming-Chih, et al.
Publicado: (2021)

Diabetes does not affect outcome in patients with Enterobacteriaceae bacteremia
por: Peralta, Galo, et al.
Publicado: (2009)

Timing of Initiating Glycopeptide Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome
por: Lee, Chen-Hsiang, et al.
Publicado: (2013)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against Staphylococcus aureus
por: Parvekar, Prashik, et al.
Publicado: (2020)

High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem non-susceptible Klebsiella pneumoniae
por: Wu, Ping-Feng, et al.
Publicado: (2016)

191. Appropriateness of Empiric Antibiotics for Enterobacteriaceae Bacteremia
por: Smith, Brandon J, et al.
Publicado: (2019)

724 Vancomycin Minimum Inhibitory Concentration Does Not Predict Death, Recurrence or Readmission in Patients with Staphylococcus aureus Bacteremia in a Safety-Net Hospital
por: Baxi, Sanjiv, et al.
Publicado: (2014)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Determination of minimum inhibitory and minimum bactericidal concentrations of Brazilian strains of Leptospira spp. for streptomycin sulphate
por: Rocha, Bruno Ribeiro, et al.
Publicado: (2020)

The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
por: Kowalska-Krochmal, Beata, et al.
Publicado: (2021)

Evaluation of clinicians’ knowledge and use of minimum inhibitory concentration values
por: Witt, Lucy S, et al.
Publicado: (2021)

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae
por: Bang, Ji Hwan, et al.
Publicado: (2013)

Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) for Twelve Antimicrobials (Biocides and Antibiotics) in Eight Strains of Listeria monocytogenes
por: Rodríguez-Melcón, Cristina, et al.
Publicado: (2021)

Minimum Inhibitory Concentrations of Equine Corynebacterium pseudotuberculosis Isolates (1996–2012)
por: Rhodes, D.M., et al.
Publicado: (2015)

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations
por: Keepers, Tiffany R., et al.
Publicado: (2015)

Developing an in silico minimum inhibitory concentration panel test for Klebsiella pneumoniae
por: Nguyen, Marcus, et al.
Publicado: (2018)

Quinolone Susceptibility in Salmonella Isolates Based on Minimum Inhibitory Concentration Determination
por: Gupta, Varsha, et al.
Publicado: (2020)

2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
por: Borjan, Jovan, et al.
Publicado: (2019)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lmgqvipi05gkgbb6sej29j1i6q